Introduction {#s1}
============

Head and neck cancer accounts for 4.8% of all cancers globally and 14.3% of all cancers in India \[[@R01]\]. In Indian setting, more than 70% of patients present in locally advanced stage and thus, local failure rates are as high as 50-70% \[[@R02], [@R03]\]. Radiotherapy (RT) alone is the standard non-surgical therapy for locally advanced head and neck carcinoma (LAHNC). For LAHNC, even the most effective RT regimens result in local control rates of 50-70% and disease-free survivals of 30-40% \[[@R04], [@R05]\]. Because of advanced disease at presentation, some of the patients are suitable only for palliative RT. The goal of treatment in these patients is to achieve prompt relief of distressing symptoms and one of the important factors that determine the treatment outcome is the quality of life (QOL). Since most of these patients have a poor performance status, prolonged duration of treatment and frequent visits to hospital compromise their QOL. Since improvement in symptoms along with QOL is an important aspect of palliation, a study without it is not worth. There have been some reports on the use of hypofractionated RT in the palliation of LAHNC but many are methodologically flawed, with limited or no toxicity data, and no assessment of QOL. There is no standard dose fractionation schedule of RT for palliative management of LAHNC. The present prospective, randomized study was planned to comparatively evaluate the efficacy, tolerability and toxicity of three schedules of palliative RT in LAHNC and assess QOL before and after RT in all groups using University of Washington Quality of Life (UWQOL) questionnaire version 4.

Methods {#s2}
=======

Patient selection {#s2a}
-----------------

The present randomized, open label, parallel study was conducted on 90 treatment-naive, histopathologically proven patients of LAHNC. Patients receiving palliative RT for LAHNC from April 2011 to June 2012 were randomly divided by simple random sampling in three groups of 30 patients each. The study was carried out after the approval of the protocol by the institution's review board. An informed consent was taken from all the patients and they were free to withdraw from the study at any point of time.

The inclusion criteria for the patients selected for the study were: Karnofsky performance status (KPS) ≥ 70, complete hemogram with Hb \> 8 g/dL, TLC \> 4,000/mm^3^, platelet count \> 100,000/mm^3^, renal function tests with blood urea \< 40 mg/dL and serum creatinine \<1.5 mg/dL, liver function tests with SGOT/PT \< 35/40 IU/L, AJCC stage III/IV and a positive biopsy for squamous cell carcinoma of head and neck. The patients having distant metastases, prior radiation, surgery or chemotherapy, KPS \< 70, pregnant or lactating patients, histopathology other than squamous cell carcinoma were excluded from the study.

Group I (Quad Shot schedule) patients were planned for radiation dose of 14.8 Gy in 4 fractions over a period of 2 days with 2 fractions per day of 3.7 Gy each, 6 h apart for two consecutive days. The same schedule was repeated for two more cycles with an interval of 3 weeks. The total planned radiation dose in this group was 44.4 Gy/12\#/6.2 weeks. Replanning with spinal cord sparing was done for last two fractions. Group II (Christie schedule) patients were planned for radiation dose of 50 Gy in 16 fractions over a period of 3.1 weeks with 3.125 Gy per fraction. Replanning with spinal cord sparing was done after 11 fractions. Group III (conventional schedule) patients were planned for radiation dose of 20 Gy in 5 fractions over a period of 5 days. The same schedule was repeated after an interval of 3 weeks. The total planned radiation dose in this group was 40 Gy/10\#/3.5 weeks. Replanning was done with spinal cord sparing for last fraction. All the patients were treated in a supine position. Two-dimensional planning was performed with a pretreatment simulation to work out the field borders which covered the primary tumor, disease extension and neck nodes. The patients were treated by parallel opposing fields and the dose was prescribed to the mid plane at the central axis. RT was delivered by cobalt-60.

Radiation reactions were assessed by Radiation Therapy Oncology Group (RTOG) criteria \[[@R06]\]. Tumor response (both primary and nodal response) was assessed by WHO response criteria either clinically or if needed, radiologically \[[@R07]\]. From the commencement of treatment, all the patients were regularly assessed daily during treatment and weekly during planned gaps in treatment. Detailed clinical evaluations were done by thorough local examination of the patients and all the patients were followed up regularly on outpatient basis for a period of at least 6 months at 1-month interval. Overall survival was measured from the day of diagnosis.

UWQOL questionnaire version 4 was used to evaluate QOL. It consists of 12 single question domains, these having between three and six response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response. The domains are pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder, taste, saliva, mood and anxiety. The physical domain score, social domain score, health-related QOL in last 7 days (HRQOL 7 days) and overall QOL were also computed \[[@R08], [@R09]\]. UWQOL questionnaire was assessed by treating radiation oncologist. The questions were translated into the local language for easy understanding of patients. The QOL was assessed at the beginning of treatment and 1 month after completion of planned treatment. The results of the study regarding completion of intended treatment, any interruptions in treatment, toxicity, local control rates and disease status at last follow-up in all the groups were documented.

Statistical analysis {#s2b}
--------------------

The data were assessed and analyzed to find out difference in all the groups with the help of SPSS software. Comparison between the groups for numeric variables was done using the Kruskal-Wallis test. Comparison between categorical measurements was done using the Chi-square test. Data were analyzed using IBM SPSS statistics 20. All P-values were two-sided and P-values \< 0.05 were considered significant. Wilcoxan signed rank test was used for assessing the difference in QOL in three arms.

Results {#s3}
=======

The patient characteristics are shown in [Table 1](#T1){ref-type="table"}. The patient parameters were comparable in the three groups. The mean dose received by the patients was 43.41 Gy in group I, 47.29 Gy in group II and 40 Gy in group III. Twenty-eight patients in group I, 25 patients in group II and all patients in group III completed intended treatment. The dropout rate was 6.67% in group I, 16.67% in group II and nil in group III. Two patients in group I left the treatment after receiving two cycles of Quad Shot, due to grade 3 skin and mucosal reactions. Five patients in group II left the treatment after receiving 10, 11 and 12 fractions, respectively in two, two and one patients, due to grade 3 skin and mucosal reactions. These patients were not excluded from the study to minimize the bias. All the patients could complete the intended treatment in group III.

###### Patient Characteristics

                                          Group I (Quad Shot)   Group II (Christie)   Group III (conventional)
  --------------------------------------- --------------------- --------------------- --------------------------
  Age, years                                                                          
    Range                                 35 - 85               28 - 77               30 - 72
    Median                                56                    51                    56
  Gender, n (%)                                                                       
    M                                     26 (86.7%)            27 (90.0%)            24 (80.0%)
    F                                     4 (13.3%)             3 (10.0%)             6 (20.0%)
  Native place, n (%)                                                                 
    Rural                                 22 (73.3%)            24 (80.0%)            25 (83.3%)
    Urban                                 8 (26.7%)             6 (20.0%)             5 (16.7%)
  KPS, n (%)                                                                          
    80                                    27 (90.0%)            28 (93.3%)            28 (93.3%)
    90                                    3 (10.0%)             2 (6.7%)              2 (6.7%)
  Site, n (%)                                                                         
    Base of tongue                        10 (33.3%)            11 (36.6%)            9 (30.0%)
    Tonsil                                7 (23.3%)             8 (26.7%)             4 (13.3%)
    Hypopharynx                           3 (10.0%)             5 (16.7%)             2 (6.7%)
    Larynx                                2 (6.7%)              3 (10.0%)             8 (22.7%)
    Vallecula                             2 (6.7%)              0 (0.0%)              2 (6.7%)
    Soft palate/ uvula                    2 (6.7%)              0 (0.0%)              1 (3.3%)
    Buccal mucosa                         0 (0.0%)              0 (0.0%)              1 (3.3%)
    Retromolar trigone                    1 (3.3%)              0 (0.0%)              1 (3.3%)
    Floor of mouth                        0 (0.0%)              1 (3.3%)              2 (6.7%)
    Anterior tongue                       3 (10.0%)             2 (6.7%)              0 (0.0%)
  Smoking, n (%)                                                                      
    Yes                                   24 (80.0%)            25 (83.3%)            23 (76.7%)
    No                                    6 (20.0%)             5 (16.7%)             7 (23.3%)
  Tobacco chewing, n (%)                                                              
    Yes                                   12 (40.0%)            13 (43.3%)            11 (36.7%)
    No                                    18 (60.0%)            17 (56.7%)            19 (63.3%)
  Histopathological distribution, n (%)                                               
    WDSCC                                 1 (3.3%)              6 (20.0%)             2 (6.7%)
    MDSCC                                 23 (76.7%)            21 (70.0%)            23 (76.7%)
    PDSCC                                 2 (6.7%)              1 (3.3%)              2 (6.7%)
    SCC(NOS)                              4 (13.3%)             2 (6.7%)              3 (10.0%)
  Stage, n (%)                                                                        
    III                                   4 (13.3%)             3 (10.0%)             3 (10.0%)
    IV                                    26 (86.7%)            27 (90.0%)            27 (90.0%)

Using UWQOL questionnaire version 4, the mean ± standard deviation scores of the individual domains, before and after radiation for group I, II and III, have been calculated and it is depicted in [Table 2](#T2){ref-type="table"}. The symptom status at presentation and after radiation treatment was documented in all the three groups. For group I, Quad Shot schedule, statistically significant improvements have been observed in scores of pain, appearance, activity, recreation, mood, anxiety, physical domain score, social domain score, HRQOL 7 days and overall QOL (20 ± 10.51 to 60 ± 23.77). Statistically significant decrement has been noted in taste and saliva score. For group II, Christie schedule, statistically significant improvements have been observed in scores of pain, appearance, activity, recreation, swallowing, mood, social domain, HRQOL 7 days and overall QOL (20 ± 3.65 to 40 ± 24.16). Statistically highly significant decrement has been noted in taste and saliva score. For group III, conventional schedule, statistically significant improvements have been observed in scores of pain, appearance, activity, recreation, swallowing, mood, anxiety, physical domain, social domain, HRQOL 7 days and overall QOL (20 ± 7.43 to 60 ± 21.87). Statistically significant excrement has been noted in taste and saliva score. Although more improvement has been observed in group I, Quad Shot schedule, in physical domain score (24, 17 and 22 patients in groups I, II and III, respectively), social domain score (28, 26 and 27 patients in groups I, II and III, respectively), HRQOL 7 days (28, 25 and 28 patients in groups I, II and III, respectively) and overall QOL (28, 26 and 27 patients in groups I, II and III, respectively), as compared to group II, Christie schedule, and group III, conventional schedule, but this was not statistically significant (using Chi-square test) and this is depicted in [Figure 1](#F1){ref-type="fig"}.

###### Assessment of Quality of Life in Locally Advanced Head and Neck University of Washington Quality of Life Questionnaire Version 4 (n = 90)

  Sr. No.   Symptom                 Group I (Quad Shot)   Group II (Christie)   Group III (conventional)                                                                       
  --------- ----------------------- --------------------- --------------------- -------------------------- ------------- --------------- --------- ------------- ------------- ---------
  1         Pain                    50 ± 15.54            100 ± 26.59           0.001\*                    50 ± 9.48     75 ± 29.16      0.002\*   50 ± 13.02    75 ± 26.21    0.001\*
  2         Appearance              50 ± 13.02            75 ± 16.08            0.000\*                    50 ± 8.64     75 ± 17.47      0.000\*   50 ± 11.37    75 ± 15.99    0.000\*
  3         Activity                50 ± 18.49            100 ± 22.36           0.000\*                    50 ± 13.27    75 ± 13.90      0.000\*   50 ± 13.13    75 ± 19.35    0.000\*
  4         Recreation              50 ± 12.60            75 ± 16.61            0.000\*                    50 ± 11.53    75 ± 14.58      0.000\*   50 ± 8.64     75 ± 16.54    0.000\*
  5         Swallowing              33 ± 28.07            67 ± 27.58            0.076                      33 ± 18.08    67 ± 30.12      0.007\*   33 ± 22.70    67 ± 27.45    0.021\*
  6         Chewing                 100 ± 28.57           75 ± 25.43            0.763                      50 ± 24.51    50 ± 24.91      0.782     100 ± 28.57   75 ± 25.43    0.782
  7         Speech                  83.5 ± 26.75          100 ± 25.55           0.968                      67 ± 16.17    67 ± 18.67      0.705     100 ± 28.30   100 ± 22.62   0.713
  8         Shoulder                100 ± 23.1            100 ± 16.99           0.414                      100 ± 12.23   100 ± 12.23     1         100 ± 23.51   100 ± 17.00   0.366
  9         Taste                   100 ± 26.55           67 ± 17.50            0.009\*                    100 ± 0.00    67 ± 22.32      0.000\*   100 ± 21.62   67 ± 24.72    0.001\*
  10        Saliva                  100 ± 0.00            67 ± 17.10            0.000\*                    100 ± 0.00    67 ± 13.83      0.000\*   100 ± 0.00    67 ± 10.76    0.000\*
  11        Mood                    25 ± 23.81            75 ± 31.03            0.001\*                    25 ± 18.28    75 ± 29.65      0.010\*   25 ± 21.51    75 ± 27.61    0.001\*
  12        Anxiety                 33 ± 21.11            67 ± 25.39            0.005\*                    33 ± 19.05    67 ± 23.92      0.216     33 ± 20.95    67 ± 22.21    0.022\*
  13        Physical domain score   50 ± 13.22            67 ± 14.63            0.043\*                    50 ± 8.83     61.33 ± 13.63   0.06      50 ± 13.91    67 ± 12.52    0.002\*
  14        Social domain score     25 ± 10.17            75 ± 31.95            0.000\*                    25 ± 0.00     62.5 ± 23.38    0.000\*   25 ± 8.64     75 ± 7.45     0.000\*
  15        HRQOL 7 days            20 ± 10.51            60 ± 22.38            0.000\*                    20 ± 3.65     40 ± 24.16      0.000\*   20 ± 7.43     60 ± 20.44    0.000\*
  16        Overall QOL             20 ± 10.51            60 ± 23.77            0.000\*                    20 ± 3.65     40 ± 24.16      0.000\*   20 ± 7.43     60 ± 21.87    0.000\*

Mean ± standard deviation score for each domain using Wilcoxan signed rank test. \*Statistically significant.

![Locally advanced head and neck cancer comparison of three palliative radiotherapy schedules on overall quality of life (n = 90). P values for group I = 0.4, group II = 0.7, group III = 0.6 (not significant).](wjon-08-007-g001){#F1}

Locoregional control after the completion of treatment was complete response (CR) (30%, 43.33% and 26.67%), partial response (PR) (53.33%, 36.67% and 50%), and no response (NR) (16.67%, 20% and 23.33%) in groups I, II and III, respectively, but this was not statistically significant (P = 0.350) and [Figure 2](#F2){ref-type="fig"} shows the same. The patients were followed for a minimum period of 6 months (range 6 - 19 months, median follow-up of 11 months). Disease status at the end of 6 months was no evidence of disease (NED) (20%, 26.67% and 13.33%), residual disease (RD) (70%, 56.67% and 76.67%), and recurrent disease (REC) (10%, 16.67% and 10%) in groups I, II and III respectively, but not statistically significant (P = 0.627). Grade III radiation skin reactions were 23.33%, 40% and 20% in groups I, II and III, respectively, not statistically significant (P = 0.175). Grade III radiation mucosal reactions were 36.66%, 53.33% and 23.33%, in groups I, II and III, respectively, statistically significant in group II, Christie schedule. Late mucosal toxicity was statistically significantly higher (P = 0.002) in group II, Christie schedule, as compared to groups I and III. The difference in pattern of failure was not statistically significant among the three groups which are shown in [Table 3](#T3){ref-type="table"}. Failure included residual, persistent and recurrent disease. Primary site failure was seen in 66.67%, 70% and 72.22% patients of groups I, II and III, respectively. Nodal failure was seen in 60%, 60% and 58.89% patients of groups I, II and III, respectively. Both primary and nodal failures were seen in 46.67%, 56.67% and 52.22% patients of groups I, II and III, respectively. Response rates were 83.33%, 80% and 76.67% for groups I, II and III, respectively, not statistically significant (P = 0.350). Median survival was 11.5 months in group I, 10.5 months in group II and 11 months in group III, not statistically significant. Overall survival rates at 1 year were 40%, 36.67% and 33.33% in group I, II and III, respectively and [Figure 3](#F3){ref-type="fig"} shows it.

![Locally advanced head and neck cancer comparison of three palliative radiotherapy schedules on locoregional control at the end of treatment (percentage). P values for overall response rate of group I = 0.5, group II = 0.6, group III = 0.3 (not significant).](wjon-08-007-g002){#F2}

###### Pattern of Failure at Last Follow-Up

  Group                    Stage           NED              Primary site failure   Nodal failure    Both primary and nodal failure
  ------------------------ --------------- ---------------- ---------------------- ---------------- --------------------------------
  Group I Quad shot        III             0/4 (0.00%)      3/4 (75.00%)           2/4 (50.00%)     1/4 (25.00%)
  IV                       6/26 (23.07%)   17/26 (65.38%)   16/26 (61.54%)         13/26 (50.00%)   
  Total                    6/30 (2.00%)    20/30 (66.67%)   18/30 (60.00%)         14/30 (46.67%)   
  Group II Christie        III             2/3 (66.67%)     1/3 (33.33%)           0/3 (0.00%)      0/3 (0.00%)
  IV                       6/27 (22.22%)   20/27 (74.07%)   18/27 (66.67%)         17/27 (62.96%)   
  Total                    8/30 (26.67%)   21/30 (70.00%)   18/30 (60.00%)         17/30 (56.67%)   
  Group III conventional   III             0/3 (0.00%)      3/3 (100.00%)          2/3 (66.67%)     2/3 (66.67%)
  IV                       4/27 (14.81%)   21/27 (77.77%)   15/27 (55.55%)         14/27 (51.85%)   
  Total                    4/30 (13.33%)   24/30 (80.00%)   17/30 (56.67%)         16/30 (53.33%)   
  All groups               18/90 (20.0%)   65/90 (72.22%)   53/90 (58.89%)         47/90 (52.22%)   

![Kaplan-Meir survival curve showing overall survival for all the groups (in months along the x-axis).](wjon-08-007-g003){#F3}

Discussion {#s4}
==========

To the best of our knowledge, this is the first open label, prospective, randomized study comparing three palliative RT schedules for the management of LAHNC. In LAHNC, surgery without adjuvant RT is associated with very poor cure rates. Compared with surgery alone, adjuvant RT resulted in an approximately 10% absolute increase in 5-year cancer-specific survival and overall survival. Chemotherapy alone is also not curative and it is used mostly along with RT. So RT with or without chemotherapy remains the mainstay of treatment in LAHNC \[[@R10]\]. Because of advanced stage at the time of presentation, the local failure rates are as high as 50-70%, despite improvement in treatment strategies for the management of LAHNC \[[@R13]\]. There is no standard dose fractionation schedule of RT for palliative management of LAHNC. Different authors have followed different schedules of total dose and numbers of fractions of RT for achieving palliation in LAHNC.

The cutaneous radiation reactions follow a definite pattern following conventional RT. In our study, the skin changes were consistent with those described in literature \[[@R06]\]. Hypofractionation has been known to produce greater overall toxicity in head and neck cancer patients. Similar trend was seen in our study. The difference in the three groups was statistically not significant. In the present study, grade 2 acute skin reaction in group I was seen in \> 50% of the patients, and grade 3 skin reaction was seen in around 20% of the patients which is in accordance to the study by Chen et al \[[@R14]\]. In group II, Christie group, grade 2 and 3 acute skin toxicity was seen in 60% and 40% of the patients, which is in accordance to the study by Al-Mamgani et al \[[@R15]\]. In group III, grade 2 and 3 acute skin toxicity was seen in \> 50% and 20% of the patients, respectively, which is similar to study by Mohanti et al \[[@R16]\]. Another hypofractionated trial for similar patients by Porceddu et al reported 26% grade 3 mucositis and 11% grade 3 skin toxicity, which supports the toxicity data in the present study \[[@R17]\].

The severity of radiation-induced mucositis depends on the total dose, fractionation and duration of therapy and associated infections \[[@R06]\]. Grade 3 acute mucosal reactions in group I was seen in approximately 30% of the patients, which is slightly higher as compared to study by Chen et al \[[@R14]\], which may be due to poor oral intake, poor hygiene or non-affordability for the medicines in the Indian setting. Grade 3 acute mucosal toxicity in group II was seen in \> 50% of the patients, which is similar to study by Al-Mamgani et al \[[@R15]\]. Grade 2 acute mucosal toxicity (\> 50%) in group III is in accordance to Mohanti et al \[[@R16]\]. By the end of the treatment grade 3 mucosal toxicity was statistically significantly (P \< 0.05) higher in group II, Christie group. RTOG grade 4 reactions were not seen in any of the patients. None of the patients in any group developed grade 4 hematological toxicity. Hematological and TLC toxicity were comparable to that reported by Chen et al \[[@R14]\].

In group I, Quad Shot, response rate at the end of the treatment was 83.33% with complete response in 30% of patients (including complete primary tumor response in 36.66% and complete nodal response in 46.6%), which is comparable to Chen et al \[[@R14]\] and Corry et al \[[@R18]\]. Our results are comparable to Carrascosa et al \[[@R19]\] and Paris et al \[[@R20]\] in providing good tumor response and palliation of symptoms \[[@R19]\]. In the present study in group II, Christie group, complete response was seen in 43.3%, partial response in 36.7%, with an overall response rate of 80%, and rest 20% patients are non-responsive. The data closely match to study by Al-Mamgani et al \[[@R15]\] and Chen et al \[[@R14]\]. In group III, response rate at the end of treatment was 76.7%, with a complete response rate of 26.7%, which is in vicinity of Chen et al \[[@R14]\] and Agarwal et al \[[@R21]\]. Acute and late reactions were acceptable \[[@R21]\]. Late radiation toxicity was observed as grade 3 cutaneous and mucosal in 3.3% in group I, 6.7% and 10% respectively in group II, which is in accordance with that reported by Corry et al \[[@R18]\], Ghoshal et al \[[@R17]\] for group I and Al-Mamgani et al \[[@R15]\] for group II, respectively.

Quality of life {#s4a}
---------------

The aim of palliative radiation is to relieve the symptoms quickly while minimizing the side effects. In addition, the treatment should be delivered in the shortest possible time considering patients' and caregivers' convenience. Ghoshal et al evaluated symptom relief and QOL in LAHNC using Quad Shot schedule \[[@R22]\]. UWQOL questionnaire was used for assessing QOL before and after radiation. After the first course, all patients had good symptom relief, improvement in QOL, and 86.7% patients had more than 50% objective response \[[@R22]\]. In another study by Ghoshal et al, at 1-month post-treatment, 100% patients with pain and \> 90% patients with dysphagia, dyspnea and insomnia experienced \> 50% symptom relief. Cough was relieved in 60% patients \[[@R23]\]. Mohanti et al treated patients with stage 4 LAHNC with a uniform dose of 20 Gy/5 fractions over 1 week. Good symptom relief (50% or more) was found in pain, dysphagia, hoarseness, otalgia, respiratory distress and cough \[[@R16]\]. Corry et al tried Quad Shot, which yielded 53% objective response. In 67% patients, the performance status stabilized or improved. The treatment was well tolerated, with overall improved QOL in 44% patients. Treatment was felt to be worthwhile by 43%, 58% and 63% of patients after first, second and third courses of cyclical radiation, respectively \[[@R18]\]. Al-Mamgani et al, by using Christie schedule, achieved excellent palliation resulting in acceptable response rates, excellent symptom control, acceptable toxicity profile and good QOL of patients \[[@R15]\]. Results from these studies are comparable to the present study. The present study shows statistically significant improvements in the physical domain score, social domain score, HRQOL 7 days and overall QOL in all the groups but these improvements are slightly higher in group I, Quad Shot group as compared to groups II and III.

Limitations and bias {#s4b}
--------------------

There are certain limitations of the study. Larger number of patients is required for a more validated result of the study. Although patients of poor socio-economic status were included in the study, some patients were not economically strong enough to purchase medicines meant for palliative management and this might have confounded the results of QOL among the groups.

Conclusion {#s4c}
----------

The aim of palliative radiation in any advanced cancer is to relieve the symptoms quickly while minimizing the side effects. In addition, the treatment should be delivered in the shortest possible time considering patients' and caregivers' convenience. To conclude, group III, conventional palliative RT schedule was tolerated by all the patients without significant problems; however, it yielded the least local control out of the three groups. Christie schedule (group II) showed better complete response than any other palliative schedule but was associated with dropout rate of 16.67% because of severe radiation reactions. The Quad Shot schedule showed optimum local control and radiation reactions amongst three groups. The present study shows a statistically significant improvement in most of the domains in all three groups but these improvements were slightly higher in Quad Shot group as compared to groups II and III. Taking into account the comparable response rate, comparable symptom relief, slightly more improvement in the post-treatment QOL, significant less toxicities than group II and least frequent hospital visits for the treatment as compared to groups II and III, group I, Quad Shot regimen may be recommended in the palliative setting in LAHNC.
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